Literature DB >> 33677469

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy.

Catarina R Almeida1, Beatriz H Ferreira1,2, Iola F Duarte3.   

Abstract

Entities:  

Year:  2021        PMID： 33677469     DOI： 10.1038/s41392-021-00530-6

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  5 in total

Review 1.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

Review 2.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

3.  PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs.

Authors:  Meryl Roudaut; Salam Idriss; Amandine Caillaud; Aurore Girardeau; Antoine Rimbert; Benoite Champon; Amandine David; Antoine Lévêque; Lucie Arnaud; Matthieu Pichelin; Xavier Prieur; Annik Prat; Nabil G Seidah; Kazem Zibara; Cedric Le May; Bertrand Cariou; Karim Si-Tayeb
Journal:  Stem Cell Reports       Date:  2021-11-04       Impact factor: 7.765

4.  Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.

Authors:  Emilie Wong Chong; France-Hélène Joncas; Nabil G Seidah; Frédéric Calon; Caroline Diorio; Anne Gangloff
Journal:  BMC Cancer       Date:  2022-10-06       Impact factor: 4.638

5.  PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages.

Authors:  Lu Wang; Shuangshuang Li; Huanhua Luo; Qi Lu; Shuwen Yu
Journal:  J Exp Clin Cancer Res       Date:  2022-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.